Mesenchymal stem cells in systemic sclerosis therapy

Abstract

Systemic sclerosis (SSc) is a rare autoimmune disorder with a high mortality rate. There are still many unknowns concerning the pathophysiology of this disease, due to its clinical heterogeneity. Since there is still no curative treatment, researchers focus on finding novel methods to help the patients. One of the valid options is cellular therapy, and mesenchymal stem cells (MSCs)-based therapy yields great expectations. These cells possess especially valuable attributes regarding key points of SSc. Nevertheless, the effectiveness and safety of this therapy must undergo a rigorous process of veri­fication. <br /> In preclinical trials, animal models proved to be a valuable source of scientific knowledge regarding SSc. Because of that, it has been possible to test autologous or allogeneic MSCs from various sources in many clinical trials. A lot of aspects still have to be determined to assess their potential in the management of SSc, probably in association with other therapies.

Posology and Serum-/Xeno-Free Engineered Adipose Stromal Cells Cell Sheets

“…Numerous studies reported the beneficial effects of using MSCs in the treatment of cartilage ( Ma et al, 2018 ), graft-versus-host disease ( Zhao et al, 2019 ), ischemia ( Oliva, 2019 ), myocardial infarction ( Luo et al, 2017 ), and sclerosis ( Dudek et al, 2020 ). In this study, osteoblast and chondrocyte cell sheets were engineered, which can be harvested and transplanted in the required areas ( Tuan et al, 2013 ; Richardson et al, 2016 ; Oryan et al, 2017 ; Yorukoglu et al, 2017 ; Abdel Meguid et al, 2018 ; Egido-Moreno et al, 2021 ).…”